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Background: The muscle Ras (MRAS) gene resides on chromosome 3q22.3 and encodes a member of the
membrane-associated Ras small GTPase proteins, which function as signal transducers in multiple processes
including cell growth and differentiation. Its role in cardiovascular disease is not fully understood yet. In a
preliminary study in heterozygous familial hypercholesterolaemia, we identified a locus linking the early onset of
coronary artery disease (CAD) to chromosome 3q.22 and elected to sequence the MRAS gene using the MegaBACE
DNA analysis system. In the present study, we investigated the association of seven single-nucleotide
polymorphisms (SNPs) at this locus with CAD and its dyslipidaemia-related risk traits in 4,650 Saudi angiographed
individuals using TaqMan assays by the Applied Biosystems real-time Prism 7900HT Sequence Detection System.
Results: Among the studied SNPs, rs6782181 (p = 0.017) and rs9818870T (p = 0.009) were associated with CAD
following adjustment for sex, age and other confounding risk factors. The rs6782181_GG also conferred risk for
obesity (1,764 cases vs. 2,586 controls) [1.16(1.03–1.30); p = 0.017], hypercholesterolaemia (1,686 vs. 2,744)
[1.23(1.02–1.47); p = 0.019], hypertriglyceridaemia (1,155 vs. 3,496) [1.29(1.01–1.45); p = 0.043] and low high-density
lipoprotein-cholesterol (lHDL-chol) levels (1,935 vs. 2,401) [1.15(1.02–1.30); p = 0.023] after adjustment. Additionally,
rs253662_(CT+TT) [1.16(1.01–1.32); p = 0.030] was associated with lHDL-chol levels. Interestingly, rs253662 (p = 0.014)
and rs6782181 (p = 0.019) were protective against acquiring high low-density lipoprotein-cholesterol (hLDL-chol) levels
(p = 0.014), while rs1720819 showed similar effects against CAD (p < 0.0001). More importantly, a 7-mer haplotype,
ACCTGAC (χ2 = 7.66; p = 0.0056), constructed from the studied SNPs, its 6-mer derivative CCTGAC (χ2 = 6.90; p =
0.0086) and several other shorter derivatives conferred risk for obesity. hLDL-chol was weakly linked to CTAA (χ2 = 3.79;
p = 0.052) and CCT (χ2 = 4.32; p = 0.038), while several other haplotypes were protective against both obesity and
hLDL-chol level.
Conclusion: Our results demonstrate that the genomic locus for the MRAS gene confers risk for CAD, obesity and
dyslipidaemia and point to the possible involvement of other genes or regulatory elements at this locus, rather than
changes in the M-Ras protein function, in these events.
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Figure 1 Homozygosity mapping for early onset of coronary
artery disease in heterozygous familial hypercholesterolaemia.
Affymetrix GT console mapping indicating the position of
homozygosity for the four affected offsprings: S3, S4, S6 and D1. FT,
father; MT, mother; S1–7, sons 1–7; D1 and 2, daughters 1 and 2.
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The MRAS gene encodes a member of the membrane-
associated family of Ras small GTPase proteins [1],
which function as signal transducers in multiple pro-
cesses including cell growth and differentiation [2-6].
With the growing number of effectors being continually
described for this GTP-binding protein superfamily
[7,8], it is becoming increasingly evident that their signal
transduction leads to the generation of a multitude of
cellular signals. Among others, these proteins play a role
in the tumour necrosis factor-alpha and MAP kinase sig-
nalling pathways [9-12]. Hence, the dysregulation of the
Ras signalling has been associated with many types of
cancers [13-17]. Notably, the M-Ras protein is ubiqui-
tously expressed but very highly so in the cardiovascular
system, particularly in the heart itself [18], intuitively
pointing to a possibly pivotal role in cardiovascular func-
tion. However, its role in cardiovascular disease is not
fully understood yet. A recent study by Erdmann et al.
[19] revealed a region on 3q22.3, which encompasses the
MRAS gene, as a risk factor for coronary artery disease
(CAD), while another study by Ellis et al. [20] proposed
that the rs9818870 at this locus is a predictor of cardio-
vascular risk in individuals free of overt heart disease.
Besides, a previous study has shown that M-Ras is
engaged in tumour necrosis factor-alpha-stimulated
lymphocyte function-associated antigen 1 activation in
splenocytes [10], thus suggesting a role in adhesion sig-
nalling, which is an important aspect of atherosclerotic
pathways [21].
Currently, there is hardly any tangible data available in
the literature pertaining to the possible role of the
MRAS gene polymorphism in cardiovascular risk traits
for CAD, such as obesity, hypertension (HTN), type 2
diabetes mellitus (T2DM) or dyslipidaemic disorders. In
a linkage study on the early onset of CAD in heterozy-
gous familial hypercholesterolaemia (HFH), we identified
a locus on chromosome (chr) 3q.22 that was linked to
both disorders (Dzimiri et al., unpublished data). Con-
sidering the fact that this locus has also been implicated
in CAD, our present study addressed the question as to
whether it might signify a link between dyslipidaemia-
related disorders and atherosclerosis onset in general, in a
homogenous cohort of 4,650 Saudi individuals harbouring
CAD and its lipid-metabolic risk traits.
Results
The initial linkage study using the Affymetrix Gene Chip
250 sty1 mapping array revealed several genomic loci,
including one on chr 3q.22, as a potential risk locus for
both the early onset of CAD and familial hypercholester-
olaemia in a family of 11 members harbouring HFH
(Figure 1). We then selected the MRAS, which resides at
this locus, as the target gene for further studies on itsrole as a risk for both CAD and dyslipidaemic disorders.
This was followed by sequencing the gene in the family
members and 200 individuals from the general population
in order to identify informative single-nucleotide polymor-
phisms (SNPs) of interest. Our results indicated that the
MRAS gene is extensively polymorphic in the Saudi popu-
lation, yielding several SNPs in both the coding and non-
coding areas of the gene. Particularly noteworthy was the
finding of a large number of intronic SNPs as well as
those residing in the 3 prime untranslated region (3′-
UTR) of the gene. This stimulated an interest for us to
examine the likelihood that these regions may consti-
tute significant risk loci for complex diseases, such as
CAD. Accordingly, we then selected seven SNPs show-
ing minor allele frequencies of >0.1 in these individuals,
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with disease. Apart from their frequencies in the above
groups, the selection of these SNPs was also partly based
on available information on their impact on disease to
allow comparison with other data in the literature. Se-
lected SNPs were rs1199338_AC (1), rs166195_CT (2),
rs253662_CT (3), rs1720819_TG (4), rs6782181_AG (5),
rs3732837_TA (6) and rs9818870_CT (7), numbered se-
quentially according to their chromosomal positional
arrangement (Figure 2). The linkage disequilibrium for
the SNPs is given in Figure 3.
The association analysis was performed in a total of
4,650 angiographed individuals, of which 2,429 had
CAD and 2,221 served as CAD-free controls. Among
the studied SNPs, rs6782181 (p = 0.017) and
rs9818870T (p = 0.009) were associated with CAD fol-
lowing adjustment for sex, age and the confounding ef-
fects of other risk factors (Table 1; see also Additional
file 1). Notably, rs6782181GG also conferred risk for
obesity (1,764 cases vs. 2,586 controls) [1.16(1.03–1.30);
p = 0.017], hypercholesterolaemia (hChol; 1,686 vs.
2,744) [1.23(1.02–1.47); p = 0.019], hypertriglyceridaemia
(hTG; 1,166 vs. 3,168) [1.29(1.01–1.45); p = 0.043] and
low high-density lipoprotein-cholesterol (lHDL-chol)
levels (1,935 vs. 2,401) [1.15(1.02–1.30); p = 0.023] fol-
lowing adjustment for the possible confounding effects
of other risk factors (Table 2; Figure 4). Additionally,
rs253662 (CT+TT) [1.16(1.01–1.32); p = 0.030] was also
implicated in the harbouring of lHDL-chol levels. One
other SNP, rs166195, lost its association with lHDL-chol
following the adjustment for confounders. Interestingly,
two of the SNPs, rs253662 (p = 0.014) and rs6782181
(p = 0.019), were protective against acquiring hLDL-chol,
whereby the former showed similar but weaker proper-
ties towards hypercholesterolaemia. One other variant,Figure 2 Schematic diagram of the MRAS (not to scale). The figure sho
chromosomal position (based on transcript NM_001252090). These SNPs wrs1720819, was protective against CAD (p < 0.0001).
Furthermore, none of the variants showed any
delineable relationship with hypertension or type 2
diabetes mellitus.
We were also interested in evaluating whether any haplo-
type was identifiable in relationship to these risk traits. We
employed the most common 7-mer haplotype, ACCTAAC
(frequency = 0.558), constructed from the studied SNPs as
a baseline for comparing their relationships with the
disease traits. Interestingly, a 7-mer haplotype, ACCTGAC
(χ2 = 7.66; p = 0.0056), its 6-mer derivative CCTGAC
(χ2 = 6.90; p = 0.0086) and other shorter derivatives
conferred risk for obesity. Another 7-mer haplotype,
ACCTAAC (χ2 = 4.63; p = 0.031), and its derivatives were
protective against obesity (Table 3; Additional file 2). Be-
sides, no notable causative association was observed be-
tween the haplotypes and changes in total cholesterol level.
Notably, apart from a 3-mer CCT (χ2 = 4.32; p = 0.038)
that was positively associated with hLDL-chol levels, the
only other haplotypes linked, but weakly so, to this trait
were the 4-mer TAAC (p = 0.057) and its 3-mer derivative
AAC (p = 0.052), both of which were actually protective to-
wards obesity (χ2 = 4.40; p = 0.036). Instead, two 7-mer
haplotypes, ATTTGAC (χ2 = 4.39; p = 0.036) and
CCCGGTT (χ2 = 4.31; p = 0.038), showed protective prop-
erties towards acquiring hLDL-chol levels.
Discussion
The present study evaluated the role of gene variants
residing at the genomic locus of the MRAS gene in CAD
and its metabolic risk factors. Our results indicate that
at least two of the studied SNPs were associated with
CAD. The finding of an association with CAD in the
present study is in agreement with the association of a
cluster of four SNPs consisting of rs1199338, rs2347252,ws studied SNPs sequentially arranged according to their
ere detected with a prevalence of >0.1 in the general population.
Table 1 Association of MRAS variants with coronary artery dis
Model Unstandardized coefficient Standardized coe
Beta S.E. Beta
Sex −0.107 0.009 −0.102
Age 0.003 0.000 0.081
FH −0.004 0.01 −0.003
T2DM 0.082 0.009 0.082
MI 0.586 0.01 0.56
HTN 0.03 0.01 0.026
OBS −0.018 0.008 −0.018
rs119338_C 0.002 0.023 0.002
rs166195_C 0.053 0.049 0.045
rs166195_T 0.038 0.048 0.033
rs253662_T −0.012 0.019 −0.009
rs1720819_T −0.182 0.052 −0.119
rs1720819_G −0.164 0.055 −0.104
rs6782181_AA 0.073 0.031 0.071
rs6782181_T 0.057 0.031 0.055
rs3732837_AA 0.013 0.022 0.009
rs3732837_T −0.027 0.043 −0.017
rs9818870_C 0.097 0.04 0.063
rs9818870_T 0.14 0.054 0.087
The table shows the significant association of the MRAS gene variants with CAD fol
CAD, T2DM type 2 diabetes mellitus, MI myocardial infarction, HTN hypertension, OBS o
**p < 0.01; ***p < 0.005.
D’ = 0.50 - 0.98; r2 = 0.02 - 0.95 
Figure 3 Linkage disequilibrium of the seven studied SNPs. The
figure displays the coefficient of the linkage disequilibrium (D’) and
the regression coefficient of the linkage disequilibrium (r2) for the
studied SNPs.
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with CAD in the study of Erdmann et al. [19]. More im-
portantly, our study also revealed that, apart from CAD,
this locus is linked to its important risk traits, obesity,
and the lipidaemic disorders, hyperlipidaemia, hyper-
triglyceridaemia and the harbouring of low HDL-
cholesterol levels. Notably, one predisposing SNP,
rs6782181, was common to CAD, obesity and the
dyslipidaemia traits, both independently and following
correction for confounding factors. Thus, our data not
only describe a relationship for this SNP with three im-
portant dyslipidaemia-related risk traits, but also suggest
a possible genomic link for these cardiovascular disease
traits at this locus. Besides, lHDL-chol levels were fur-
ther associated with the dominant inheritance mode for
rs253662 and weakly linked to that for the rs166195.
Therefore, put together, our results point to the genomic
locus for the MRAS gene as conferring risk for CAD and
its important metabolic risk traits.
Interestingly, the association of rs253662 with the
harbouring of low HDL-cholesterol levels is in direct
contrast to its protective effects on the acquisition of
high LDL-cholesterol and similar but weaker properties
towards elevated total cholesterol levels. Currently, apart
from a study implicating the rs9818870 as a predictor ofease
fficient t p value 95.0% C.I. for beta
Lower bound Upper bound
−12.05 0.000*** −0.125 −0.09
8.53 0.000*** 0.002 0.003
−0.401 0.689 −0.024 0.016
9.034 0.000*** 0.064 0.1
59.874 0.000*** 0.567 0.605
2.907 0.004*** 0.01 0.05
−2.177 0.03* −0.035 −0.002
0.106 0.915 −0.043 0.048
1.076 0.282 −0.044 0.15
0.785 0.433 −0.057 0.133
−0.622 0.534 −0.049 0.026
−3.505 0.000*** −0.284 −0.08
−2.996 0.003** −0.272 −0.057
2.379 0.017* 0.013 0.133
1.816 0.069 −0.005 0.118
0.58 0.562 −0.03 0.056
−0.643 0.52 −0.111 0.056
2.416 0.016* 0.018 0.176
2.612 0.009** 0.035 0.246
lowing Bonferroni correction. Beta, odds ratio coefficient; FH family history of
besity, C.I confidence interval, S.E. standard error; t, standard t test. *p < 0.05;
Table 2 Association of MRAS gene with obesity and dyslipidaemia
Variant Controls Cases Univariate analysis Multivariate analysis
Exp(B) (95% C.I.) p value Exp(B) (95% C.I.) p value
Obesity
rs6782181_GG 0.153 0.397 1.15(1.02–1.29) 0.023* 1.16(1.03–1.30) 0.017*
Hypercholesterolaemia
rs253662_TT 0.051 0.038 0.73(0.59–0.90) 0.041* 0.74(0.53–1.01) 0.054
rs6782181_GG 0.015 0.022 1.47(1.07–2.03) 0.018* 1.23(1.02–1.47) 0.019*
Low HDL levels
rs166195_CT+TT 0.356 0.385 1.14(1.00–1.29) 0.047* 1.00(0.99–1.00) 0.961
rs253662_CT+TT 0.318 0.344 1.13(0.99–1.29) 0.064 1.16(1.01–1.32) 0.030*
rs6782181_GG 0.151 0.167 1.13(1.00–1.27) 0.045* 1.15(1.02–1.30) 0.023*
High LDL-cholesterol
rs253662_T 0.192 0.162 0.82(0.70–0.96) 0.013* 0.82(0.69–0.96) 0.014*
rs253662_CT+TT 0.336 0.291 0.82(0.67–0.98) 0.028* 0.81(0.68–0.98) 0.030*
rs6782181_G 0.387 0.356 0.88(0.77–0.99) 0.038* 0.88(0.77–0.99) 0.040*
rs6782181_AG+GG 0.614 0.564 0.82(0.68–0.97 0.019* 0.81(0.68–0.97) 0.019*
Hypertriglyceridaemia
rs6782181_G 0.152 0.175 1.19(1.00–1.42) 0.067 1.29(1.01–1.45) 0.043*
The table shows the MRAS variants associated with the disease traits. B, odds ratio; C.I., confidence interval. *p < 0.05.
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ease, there is hardly any literature describing the rela-
tionship between the MRAS gene or this genomic locus
and lipid metabolic disorders. Thus, to our knowledge,
this is the first report implicating this region in obesity
and dyslipidaemia.
We further evaluated the possibility that haplotypes
might be more informative than the individual SNPs in
discerning the impact of the gene on disease. It was re-
markable that a haplotype constructed from these SNPs
and several of its shorter derivatives conferred risk for
obesity, displaying a much higher level of significance
for the relationships than the individual variants. Even
















OBS                hChol lHDL-c
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Figure 4 Association of MRAS genotypes with disease traits.unequivocally associated with these haplotypes was
obesity. If anything, for the other disease traits, the large
majority of the associations were actually protective
against acquiring high LDL-chol, in line with the ob-
served protective actions of the individual SNPs. These
observations can be conceived as confirming the im-
portance of this genomic region as a specific risk for
obesity. The weak association of haplotypes with the
dyslipidaemic traits may indicate that the influence of
the gene on dyslipidaemia-related events may be
driven primarily through the interaction of the gene
with obesity.
The interesting question is whether or not this locus
might provide a mechanistic link between dyslipidaemiahol hLDL-chol hTG
l Cases
Table 3 Association of MRAS haplotypes with obesity and high low-density lipoprotein levels
Block Haplotype Pooled Cases Control χ2 p value
Obesity
1–7 ACCTAAC 0.558 0.541 0.565 4.63 0.031
ACCTGAC 0.035 0.042 0.031 7.66 0.0056*
1–6 ACCTAA 0.558 0.541 0.564 4.60 0.032
ACCTGA 0.036 0.044 0.032 8.28 0.004**
2–7 CCTAAC 0.56 0.543 0.567 4.61 0.032
CCTGAC 0.035 0.042 0.032 6.90 0.0086*
3–7 CTAAC 0.614 0.597 0.618 3.74 0.053
CTGAC 0.04 0.047 0.036 7.15 0.0075*
1–5 ACCTA 0.558 0.541 0.564 4.36 0.039
ACCTG 0.037 0.045 0.033 9.22 0.0024**
4–7 TAAC 0.618 0.601 0.623 4.40 0.036
High LDL-cholesterol
1–7 ATTTGAC 0.172 0.153 0.177 4.39 0.036
CCCGGTT 0.058 0.045 0.060 4.31 0.038
2–7 TTTGAC 0.173 0.152 0.179 5.11 0.024
CCGGTT 0.062 0.046 0.064 6.27 0.012
1–6 ATTTGA 0.172 0.152 0.177 4.54 0.033
1–5 ATTTG 0.172 0.152 0.176 4.49 0.034
2–6 TTTGA 0.173 0.151 0.178 5.45 0.019
4–7 TAAC 0.618 0.640 0.612 3.61 0.057
GGTT 0.061 0.048 0.064 4.81 0.028
1–4 ATTT 0.174 0.153 0.179 4.92 0.027
3–6 CTAA 0.613 0.635 0.606 3.79 0.052
TTGA 0.181 0.158 0.187 6.02 0.014
2–5 TTTG 0.174 0.152 0.179 5.23 0.022
1–3 ATT 0.175 0.154 0.180 5.01 0.025
5–7 AAC 0.620 0.642 0.613 3.78 0.052
2–4 CCT 0.638 0.663 0.632 4.32 0.038
The table shows selected haplotypes constructed from combinations of the studied variants. The most frequent 7-mer haplotype, ACCTAAC (0.558), was employed
as the baseline haplotype to determine the relative effects of the associated haplotypes. The minor allele frequency and control and case haplotype frequencies
are proportions. Number 1 denotes rs1199338_AC, 2 is rs166195_CT, 3 is rs253662_CT, 4 is rs1720819_TG, 5 is rs6782181_AG, 6 is rs3732837_AT and 7 is
rs9818870_CT, arranged sequentially by their chromosomal positions, and blocks represent the variant constituting the respective haplotypes. *p < 0.01; **p < 0.005 by
the χ2 test.
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tions seem to suggest a direct link of the mechanisms in-
volved in these events at the genomic level to some
function of this locus. Particularly noteworthy is the fact
that the studied variants are either intronic or reside in
the 3′-UTR relative to the MRAS gene sequence. This
implies that the effects of the studied variants are not
likely to be directly related to functional changes of M-
Ras protein per se. Thus, while no speculations can be
made of the mechanisms involved in these interactions,
based on the current findings alone, it can nonetheless
be inferred that other yet unidentified genes/entities at
the chromosome 3q.22 locus may ultimately be respon-sible for the observed manifestations and might offer a
link between dyslipidaemia and pathways leading to ath-
erosclerosis. Such mechanisms, particularly those related
to SNPs in the 3′-UTR may involve some gene regula-
tory entities embedded in the function of this genomic
region. Genetic hitchhiking might also explain the asso-
ciation of particularly the intragenic non-coding SNPs,
as a result of the variants being linked with a causative
mutation on the M-Ras through positive selection at this
locus [22-24] or some spatial selection pressures [25-29].
However, further speculation on this possibility is be-
yond the scope of the present work. Hence, further stud-
ies are needed to look into these possibilities.
Alshahid et al. Human Genomics 2013, 7:15 Page 7 of 10
http://www.humgenomics.com/content/7/1/15Conclusions
In conclusion, our study suggests that the genomic locus
for the MRAS gene confers risk for CAD, obesity and
dyslipidaemia. However, our findings point to the in-
volvement of other genes or factors, rather than changes
in the M-Ras protein function, as the possible under-
lying cause for the observed events.
Methods
Study population
The initial linkage study was performed in a family of 11
individuals with HFH, in which the primary proband
underwent triple bypass surgery at the age of 14 years.
Following the identification of chromosome 3q.22 as a
potential locus for this disorder as well as the early onset
of CAD, we elected to sequence the MRAS gene in the
family and 200 other individuals from the general popu-
lation. We then embarked on a case-control study in a
total of 4,650 individuals consisting of 2,429 CAD pa-





Agea 53.8 ± 0.5 56.4 ± 0.3












(relative to coronary artery disease)
Age 50.6 ± 0.4 51.2 ± 0.5
BMI 29.0 ± 0.2 27.97 ± 0.2
Total chol 4.51 ± 0.02 4.42 ± 0.03
HDL-chol 1.26 ± 0.01 1.18 ± 0.03
LDL-chol 2.76 ± 0.02 2.73 ± 0.03
TG 1.52 ± 0.02 1.60 ± 0.03
FG 6.87 ± 0.16 6.80 ± 0.23
BP 120/83 119/81
The numbers in brackets give the fraction of the total (all) values of the group. BMI
myocardial infarction, FG fasting glucose, T2DM type 2 diabetes mellitus, lHDLC low
cholesterol, hTG hypertriglyceridaemia, hChol hypercholesterolaemia, HTN hypertenyears) with angiographically determined narrowing of
the coronary vessels by at least 50% and 2,221
angiographed controls (1,189 males and 1,032 females,
mean age 53.8 ± 0.5 years). The controls for CAD were
a group of individuals undergoing surgery for heart
valvular diseases, and those who may have reported with
chest pain, but were established to have no significant
coronary stenosis by angiography. Among these, 3,060
individuals had established MI. The primary patient sub-
set of interest in this population comprised 1,764 obese
individuals with a body mass index of ≥30.0 kg/m2
(Table 4). Furthermore, 3,541 individuals had primary
(essential) HTN, defined as ≥140 mmHg systolic blood
pressure or ≥90 mmHg diastolic pressure based on The
Sixth Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC VI) criteria [30]. Accordingly, es-
sential, primary or idiopathic hypertension is defined as
high blood pressure in which secondary causes such as
renovascular disease, renal failure, pheochromocytoma,ts
Cases
Female All Male Female
700(0.27) 1,764 967(0.55) 797(0.45)
51.1 ± 0.7 55.6 ± 0.4 55.5 ± 0.4 55.7 ± 0.4
25.2 ± 0.1 34.9 ± 0.2 33.8 ± 0.1 35.9 ± 0.2
1,032(0.46) 2,429 1,860(0.66) 569(0.34)
803(0.51) 3,060 2,262(0.74) 798(0.26)
1,283(0.34) 920 602(0.65) 318(0.35)
754(0.36) 2,560 1,713(0.55) 847(0.45)
374(0.34) 3,541 2,314(0.65) 1,227(0.35)
1,029(0.41) 1,935 1,487(0.77) 448(0.23)
1,029(0.25) 860 634(0.74) 226(0.26)
943(0.34) 1,686 1,117(0.66) 569(0.34)
1,140(0.36) 1,166 829(0.71) 337(0.29)
1,477(0.53) 1,771 1,694(0.96) 77(0.04)
49.8 ± 0.5 60.3 ± 0.2 59.8 ± 0.3 61.8 ± 0.54
30.3 ± 0.3 28.9 ± 0.1 28.3 ± 0.1 31.0 ± 0.3
4.62 ± 0.03 4.48 ± 0.02 4.43 ± 0.03 4.66 ± 0.05
1.33 ± 0.01 1.15 ± 0.01 1.15 ± 0.01 1.25 ± 0.02
2.80 ± 0.03 2.71 ± 0.02 2.68 ± 0.02 2.84 ± 0.06
1.44 ± 0.03 1.78 ± 0.02 1.78 ± 0.03 1.78 ± 0.05
6.92 ± 0.22 9.45 ± 0.31 9.27 ± 0.37 9.88 ± 0.56
121/82 128/84 130/85 127/83
body mass index, CAD coronary artery disease, FH family history of CAD, MI
high-density lipoprotein-cholesterol, hLDLC high low-density lipoprotein-
sion. aValues relative to obesity as the case group.
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or Mendelian forms (monogenic) are not present [30].
The third subset of interest was composed of 2,560 indi-
viduals with T2DM (formerly known as non-insulin-
dependent diabetes mellitus or adult-onset diabetes).
The National Diabetes Data Group of the USA and the
Second World Health Organization Expert Committee
on Diabetes Mellitus [31] defined type 2 diabetes
mellitus as a metabolic disorder that is characterized by
high blood glucose (generally defined as a fasting glucose
level >126 mg/dl) in the context of insulin resistance
and relative insulin deficiency. Among these subsets of
patients, some individuals harboured a combination of
two or possibly three of the cardiovascular risk traits.
The overall exclusion criteria for the disease cases were
major cardiac rhythm disturbances, incapacitating or
life-threatening illness, major psychiatric illness or sub-
stance abuse, history of cerebral vascular disease, neuro-
logical disorder and the administration of psychotropic
medication. Exclusion criteria for the controls were,
among others, diseases such as cancer, autoimmune
disease or any other disorders likely to interfere with
the variables under investigation. All participants
signed an informed consent, and the study was
performed in accordance with the regulations laid
down by the King Faisal Specialist Hospital and Re-
search Centre Ethics Committee in compliance with
the Helsinki Declaration [32].
Linkage analysis and screening for mutations
Five millilitres of peripheral blood was sampled in EDTA
tubes from each of the study individuals after obtaining
their written consent, and genomic DNA was extracted
from leukocytes by the standard salt method using
Gentra PUREGENE DNA isolation kit (Qiagen Sciences,
Germantown, MD, USA). For the genome-wide scanning
with the Affymetrix Gene Chip 250 sty1 mapping array
(Affymetrix Inc., Santa Clara, CA, USA), 250 ng of gen-
omic DNA was digested with the restriction endonucle-
ase StyI, mixed with Sty1 adaptors and ligated with T4
DNA ligase. The mixture was added to four separate
polymerase chain reactions (PCRs), amplified, pooled
and purified to remove the unincorporated dNTPs. The
PCR product was then fragmented, biotinylated, hybri-
dized to the 250 sty1 array for 18 h, washed, stained and
scanned as recommended by the manufacturer. SNP
genotypes, linear chromosomal locations and marker or-
dering were accomplished using the Affymetrix Geno-
typing Console (GC) Software version 3.02 (Affymetrix,
Inc., Santa Clara, CA, USA). Extended blocks or regions
of homozygosity (ROHs) were identified using the GC
software. Conventionally, ROHs are defined as stretches
of consecutive alleles in affected individuals and hetero-
zygous or homozygous for the other allele in unaffectedmembers of the same family. For the linkage analysis,
multipoint parametric linkage analysis was performed
using the GeneHunter Easy Linkage Analysis Software
4.0 module for estimating the LOD scores. The disease
was assumed to be an autosomal dominant trait with
100% penetrance. Copy Number Analyzer for GeneChip®
Ver. 3.0 (Affymetrix, Inc., Santa Clara, CA, USA) was
employed to check the shared chromosomal regions of
homozygosity.
Sequencing of the MRAS gene
The sequencing of the MRAS gene was accomplished
using the MegaBACE DNA analysis system (Amersham
Biosciences, Sunnyvale, CA, USA). Briefly, the DNA was
subjected to PCR by standard methods described else-
where. Five microlitres of PCR product was then treated
with 2 μl of ExoSAP-IT (USB Corporation, Cleveland,
OH, USA) at 37°C for 30 min to allow the hydrolytic
removal of excess primers by exonuclease 1 and shrimp
alkaline phosphatase. The enzymes were inactivated at
80°C for 15 min, and the sequencing reaction was initi-
ated by mixing 2 μl of DNA, 1 μl of 5 μmol primer, 8 μl
of DYEnamic ET Dye Terminator (Amersham Biosciences,
Amersham, Buckinghamshire, UK) and 9 μl of distilled
water. The mixture was thermally cycled 40× at 95°C for
20 s, 50°C for 15 s and 60°C for 1 min. Unincorporated
dye-labelled terminators were removed by gel filtration
through the DyeEx 96 plate (Qiagen, GmbH, Hilden,
Germany). The eluent was vacuum-dried and dissolved in
10 μl of loading solution (GE Healthcare UK Ltd, Little
Chalfont, Buckinghamshire, UK) for sequencing. Data
were analyzed for SNPs using the Lasergene software
(DNASTAR, Inc., Madison, WI, USA).
Association experiments
Once the SNPs of interest were identified, genotyping
was achieved by TaqMan chemistry using the Applied
Biosystems real-time Prism 7900HT Sequence Detection
System (ABI Inc., Foster City, CA, USA). Primers and
the TaqMan fluorogenic probes bearing a suitable
reporter dye on the 5′-end and a quencher dye on the
3′-end were designed using the Primer Express Software
V2.0 (ABI Inc., Foster City, CA, USA) and procured
from Applied Biosystems (ABI, Warrington, UK). One
probe (for allele 1) was labelled with VIC dye and the
other (for allele 2) with FAM dye at the 5′-end, and ser-
ial dilutions were run to determine the optimal working
concentration. For each reaction, a 25-μl reaction was
prepared by mixing 5 μl of 50 ng DNA, 12.5 μl of 2×
Universal mix (Eurogentec, Liege Science Park, Seraing,
Belgium), 1.25 μl of 20× probe assay mix and 6.25 μl of
DNase-free distilled water. Three no-template controls
were included in each plate for the normalization of
emission signal. The thermal profile for amplification for
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10 min, followed by 40 cycles of 94°C for 15 s and 60°C
for 30 s. The plates were then scanned for FRET signal
using the 7900HT Sequence Detection System and data
analyzed using the SDS 2.0 software (ABI Inc., Foster
City, CA, USA).Statistical analysis
Comparison of genotypes and alleles between different
groups for continuous dependent variables was achieved
by analysis of variance or Student's t test as appropriate.
Categorical variables were analyzed by chi-square test.
Univariate and multiple logistic regression analyses were
used to compute odds ratios and their 95% confidence
intervals as well as to determine the confounding effects
of the different cardiovascular risk traits on the individ-
ual respective relationships. The haplo.stats package [33]
in the R Statistical Computing software [34] was used to
perform haplotype-based association analysis. Odds ra-
tios for haplotypes were calculated using as reference
the most frequent 7-mer haplotype, ACCTAAC (fre-
quency = 0.558), and the Haplotype Score statistic for
the association of a haplotype with the binary trait was
calculated as in Schaid et al. [35] and Lake et al. [36].
The significance of association was determined between
haplotypes and the case-control status - a binomial trait
denoting whether or not a patient had the disease. All
other statistical analyses were performed using the SPSS
version 20 software (SPSS Inc., Chicago, IL, USA), and
data are expressed as mean ± SEM. Associations with a
two-tailed p value <0.05 were considered statistically
significant.Additional files
Additional file 1: Statistical analysis for the association of MRAS
variants with disease. The file contains the analyses of the MRAS gene
with coronary artery disease and obesity and the univariate and
multivariate analyses for the MRAS variants displaying a significant
association with the disease traits.
Additional file 2: Analysis of the association of MRAS haplotypes
with disease. The file contains a table showing the haplotypes
constructed from combinations of the studied variants with respect
to obesity.Abbreviations
3′-UTR: 3 prime untranslated region; BP: Blood pressure; CAD: Coronary artery
disease; FG: Fasting glucose; FH: Family history of CAD;
hChol: Hypercholesterolaemia; HDLC: High-density lipoprotein-cholesterol;
hTG: Hypertriglyceridaemia; HTN: Hypertension; LDLC: Low-density
lipoprotein-cholesterol; MI: Myocardial infarction; MRAS: Membrane-
associated muscle Ras small GTPase gene; OBS: Obesity; SNP: Single-
nucleotide polymorphism; T2DM: Type 2 diabetes mellitus.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
MA supervised the recruitment of the patients and compliance with
institutional ethical procedures. SMW performed the gene mapping analysis.
MA-N was responsible for overall running the TaqMan assays. NPM was
involved in running the Affymetrix assays, designing the probes, screening
for gene mutations as well as participating in the write up of the manuscript.
SE performed part of the sequencing experiments. SH ran the Affymetrix
assays. DG contributed to running the TaqMan assays. EA performed the
DNA isolation and maintained the patient database. NM was responsible for
clinical patient data and material acquisition. BFM contributed to the write
up of the manuscript. ND is the principal investigator, with the overall
responsibility of the project and the preparation of the manuscript. All
authors read and approved the final manuscript.Acknowledgements
This study was supported through the Royal Cardiovascular Research Grant
(RAC2030012) under the King Faisal Specialist Hospital and Research Centre
for which the authors wish to express their gratitude.
Author details
1King Faisal Heart Institute, MBC-16, King Faisal Specialist Hospital and
Research Centre, Riyadh 11211, Saudi Arabia. 2Genetics Department, MBC-03,
King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi
Arabia.
Received: 9 April 2013 Accepted: 13 May 2013
Published: 5 June 2013References
1. Kimmelman A, Tolkacheva T, Lorenzi MV, Osada M, Chan AM: Identification
and characterization of R-ras3: a novel member of the RAS gene family
with a non-ubiquitous pattern of tissue distribution. Oncogene 1997,
15(22):2675–2685.
2. Quilliam LA, Castro AF, Rogers-Graham KS, Martin CB, Der CJ, Bi C: M-Ras/R-Ras3,
a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-
activating protein, interacts with the putative Ras effector AF6. J Biol Chem
1999, 274(34):23850–23857.
3. Watanabe-Takano H, Takano K, Keduka E, Endo T: M-Ras is activated by
bone morphogenetic protein-2 and participates in osteoblastic
determination, differentiation, and transdifferentiation. Exp Cell Res 2010,
316(3):477–490.
4. Harrisingh MC, Lloyd AC: Ras/Raf/ERK signalling and NF1. Cell Cycle 2004,
3(10):1255–1258.
5. Liebmann C: Regulation of MAP kinase activity by peptide receptor
signalling pathway: paradigms of multiplicity. Cell Signal 2001,
13(11):777–785.
6. Kerkhoff E, Rapp UR: Cell cycle targets of Ras/Raf signalling. Oncogene
1998, 17(11 Reviews):1457–1462.
7. Chakraborti S, Chakraborti T: Oxidant-mediated activation of mitogen-
activated protein kinases and nuclear transcription factors in the
cardiovascular system: a brief overview. Cell Signal 1998, 10(10):675–683.
8. Chong H, Vikis HG, Guan KL: Mechanisms of regulating the Raf kinase
family. Cell Signal 2003, 15(5):463–469.
9. Ehrhardt GR, Leslie KB, Lee F, Wieler JS, Schrader JW: M-Ras, a widely expressed
29-kD homologue of p21 Ras: expression of a constitutively active mutant
results in factor-independent growth of an interleukin-3-dependent cell line.
Blood 1999, 94(7):2433–2444.
10. Yoshikawa Y, Satoh T, Tamura T, Wei P, Bilasy SE, Edamatsu H, Aiba A,
Katagiri K, Kinashi T, Nakao K, Kataoka T: The M-Ras-RA-GEF-2-Rap1
pathway mediates tumor necrosis factor-alpha dependent regulation of
integrin activation in splenocytes. Mol Biol Cell 2007, 18(8):2949–2959.
11. Kimmelman AC, Osada M, Chan AM: R-Ras3, a brain-specific Ras-related
protein, activates Akt and promotes cell survival in PC12 cells. Oncogene
2000, 19(16):2014–2022.
12. Louahed J, Grasso L, De Smet C, Van Roost E, Wildmann C, Nicolaides NC,
Levitt RC, Renauld JC: Interleukin-9-induced expression of M-Ras/R-Ras3
oncogene in T-helper clones. Blood 1999, 94(5):1701–1710.
13. Muto S, Katsuki M, Horie S: Rapid induction of skin tumors in human but
not mouse c-Ha-ras proto-oncogene transgenic mice by chemical
carcinogenesis. Cancer Sci 2006, 97(9):842–847.
Alshahid et al. Human Genomics 2013, 7:15 Page 10 of 10
http://www.humgenomics.com/content/7/1/1514. Abuli A, Fernandez-Rozadilla C, Giraldez MD, Munoz J, Gonzalo V, Bessa X,
Bujanda L, Rene JM, Lanas A, Garcia AM, Salo J, Arguello L, Vilella A, Carreno
R, Jover R, Xicola RM, Llor X, Carvajal-Carmona L, Tomlinson IP, Kerr DJ,
Houlston RS, Pique JM, Carracedo A, Castells A, Andreu M, Ruiz-Ponte C,
Castellvi-Bel S: A two-phase case–control study for colorectal cancer
genetic susceptibility: candidate genes from chromosomal regions 9q22
and 3q22. Br J Cancer 2011, 105(6):870–875.
15. Guo X, Schrader KA, Xu Y, Schrader JW: Expression of a constitutively
active mutant of M-Ras in normal bone marrow is sufficient for
induction of a malignant mastocytosis/mast cell leukemia, distinct from
the histiocytosis/monocytic leukemia induced by expression of activated
H-Ras. Oncogene 2005, 24(14):2330–2342.
16. Zhang KX, Ward KR, Schrader JW: Multiple aspects of the phenotype of
mammary epithelial cells transformed by expression of activated M-Ras
depend on an autocrine mechanism mediated by hepatocyte growth
factor/scatter factor. Mol Cancer Res 2004, 2(4):242–255.
17. Wang D, Yang W, Du J, Devalaraja MN, Liang P, Matsumoto K, Tsubakimoto
K, Endo T, Richmond A: MGSA/GRO-mediated melanocyte transformation
involves induction of Ras expression. Oncogene 2000, 19(40):4647–4659.
18. MRAS (muscle RAS oncogene homolog). http://biogps.org/#goto=genereport
&id=22808.
19. Erdmann J, Grosshennig A, Braund PS, Konig IR, Hengstenberg C, Hall AS,
Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, Cambien F, Bruse P,
Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R,
Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D,
Merlini PA, Peyvandi F, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, et al:
New susceptibility locus for coronary artery disease on chromosome 3q22.3.
Nat Genet 2009, 41(3):280–282.
20. Ellis KL, Frampton CM, Pilbrow AP, Troughton RW, Doughty RN, Whalley GA,
Ellis CJ, Skelton L, Thomson J, Yandle TG, Richards AM, Cameron VA:
Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated
with subsequent cardiovascular outcomes in healthy controls and
in established coronary artery disease. Circ Cardiovasc Genet 2001,
4(6):636–646.
21. Galkina E, Ley K: Vascular adhesion molecules in atherosclerosis.
Arterioscler Thromb Vasc Biol 2007, 27(11):2292–2301.
22. Mäkinen HS, Shikano T, Cano JM, Merilä J: Hitchhiking mapping reveals a
candidate genomic region for natural selection in three-spined
stickleback chromosome VIII. Genetics 2008, 178(1):453–465.
23. Barton NH: Genetic hitchhiking. Philos Trans R Soc Lond B Biol Sci 2000,
355(1403):1553–1562.
24. Yeaman S: Genomic rearrangements and the evolution of clusters of
locally adaptive loci. Proc Natl Acad Sci USA 2013, 110(19):E1743–E1751.
25. Schneider KA, Kim Y: Genetic hitchhiking under heterogeneous spatial
selection pressures. PLoS One 2013, 8(4):e61742.
26. Barton NH, Etheridge AM, Kelleher J, Veber A: Genetic hitchhiking in
spatially extended populations. Theor Popul Biol. in press.
27. Desai MM, Walczak AM, Fisher DS: Genetic diversity and the structure
of genealogies in rapidly adapting populations. Genetics 2013,
193(2):565–585.
28. Flaxman SM, Feder JL, Nosil P: Spatially explicit models of divergence and
genome hitchhiking. J Evol Biol 2012, 25(12):2633–2650.
29. Kim Y: Stochastic patterns of polymorphism after a selective sweep over
a subdivided population. Genet Res 2013. doi:10.1017/S0016672313000062.
30. Dzimiri N, Al-Najai M, Elhawari S, Gueco D, Vigilla MG, Andres E, Muiya P,
Mazher N, Alshahid M, Meyer BF: The interaction of Agt gene
polymorphism with cardiovascular risk traits in atherosclerosis.
Arterioscler Thromb Vasc Biol 2012, 32(5_MeetingAbstracts):A524.
31. American Heart Association: Arteriosclerosis, Thrombosis, and Vascular
Biology Annual Conference 2007. Arterioscler Thromb Vasc Biol 2007,
27(6):e35–e137.
32. WMA Declaration of Helsinki - ethical principles for medical research involving
human subjects. http://www.wma.net/en/30publications/10policies/b3/index.
html.33. Schaid DJ: Statistical genetics and genetic epidemiology. http://mayoresearch.
mayo.edu/mayo/research/schaid_lab/software.cfm.
34. The R Project for Statistical Computing. http://www.r-project.org/.
35. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for
association between traits and haplotypes when linkage phase is
ambiguous. Am J Hum Genet 2002, 70(2):425–434.
36. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ:
Estimation and tests of haplotype-environment interaction when linkage
phase is ambiguous. Hum Hered 2003, 55(1):56–65.
doi:10.1186/1479-7364-7-15
Cite this article as: Alshahid et al.: New susceptibility locus for obesity
and dyslipidaemia on chromosome 3q22.3. Human Genomics 2013 7:15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
